Oxford researchers report positive early trial results for COVID-19 vaccine candidate

Researchers at Oxford University say early-stage results from a Phase I/II clinical trial of a SARS-CoV-2 vaccine candidate display safety and strong immune responses.

Results, published in The Lancet, revealed that the vaccine is safe, causes few side effects and induces strong immune responses in both parts of the immune system in the fight against COVID-19, which is caused by SARS-CoV-2.

Get the full story at our sister site, MassDevice.

---

Filed Under: clinical trials, Drug Discovery and Development, Infectious Disease
Tagged With: AstraZeneca plc, BioNTech, coronavirus, covid-19, Oxford, Pfizer
 

---